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Abstract: The response to treatment and progression of Chronic Obstructive Pulmonary 
Disease (COPD) varies significantly. Small airways disease (SAD) is being increasingly 
recognized as a key pathological feature of COPD. Studies have brought forward patholo-
gical evidence of small airway damage preceding the development of emphysema and the 
detection of obstruction using traditional spirometry. In recent years, there has been 
a renewed interest in the early detection of SAD and this has brought along an increased 
demand for physiological tests able to identify and quantify SAD. Early detection of SAD 
allows early targeted therapy and this suggests the potential for altering the course of disease. 
The aim of this article is to review the evidence available on the physiological testing of 
small airways. The first half will focus on the role of lung function tests such as maximum 
mid-expiratory flow, impulse oscillometry and lung clearance index in detecting and quanti-
fying SAD. The role of Computed Tomography (CT) as a radiological biomarker will be 
discussed as well as the potential of recent CT analysis software to differentiate normal aging 
of the lungs to pathology. The evidence behind SAD biomarkers sourced from blood as well 
as biomarkers sourced from sputum and broncho-alveolar lavage (BAL) will be reviewed. 
This paper focuses on CC-16, sRAGE, PAI-1, MMP-9 and MMP-12.
Keywords: spirometry, targeted treatment, normal aging, pathological process
Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder, char-
acterized by irreversible airway obstruction.1 It is widely recognized that disease of 
the small airways contributes hugely to this obstruction.2,3 Colloquially referred to 
as the “silent zone” of the lungs, it is estimated that 75% of the small airways must 
first be destroyed before changes in standard lung function are observed.4 The 
number of small airways is reportedly lower in mild COPD patients, compared to 
controls, with the number depleting with increasing GOLD stage.5
Understanding of early pathological changes is particularly important, given the 
suggestion that disease of the small airways precedes emphysema in COPD 
patients; micro-CT performed in ex vivo lungs revealed loss of terminal bronchioles 
occurred before emphysematous changes.5,6 In a recent longitudinal study, 70% of 
a COPD cohort followed a disease progression trajectory, whereby small airway 
and emphysematous changes preceded large airway abnormalities.7
Despite the advent of several physiological tests of the small airways, none have 
yet been validated for use in the clinical assessment of COPD. The aim of this 
review is to discuss current physiological testing of the small airways, and how the 
underlying mechanisms may contribute to our understanding. We will allude to the 
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use of potential biological markers that, following further 
validation, may serve as predictors of early disease and 
disease progression.
Methods
Using Ovid, the following databases – Medline (1946 to 
April 20) and Embase (1974 to April 2020) including the 
Cochrane Library were searched. The search was limited 
to papers written in English and that had been published in 
the last 20 years. To ensure a thorough review we con-
ducted literature searches using the following terms: 
“small airways disease”, “COPD”, “spirometry”, “oscillo-
metry”, “lung clearance index/LCI”, “maximum mid- 
expiratory flow/MMEF”, “Computed Tomography/CT”, 
“Parametric Response Mapping/PRM”, “biomarker”, 
“sputum”, “bronchoalveolar lavage/BAL”, “plasma”, 
“serum”. Boolean Operators AND and OR were used to 
find the most relevant papers. Titles and abstracts were 
reviewed within the study team for inclusion and relevant 
findings summarized within sections that focus on each 
pathophysiological mechanism or biomarker in turn. 
Papers older than 20 years were used as reference when 
there was no other suitable latest alternative.
Lung Function Testing to Detect SAD
As mentioned earlier, COPD is a heterogenous disorder.8,9 
Its clinical presentation, progression, clinical response to 
treatment, imaging and physiological changes vary signif-
icantly. The main pathological processes driving COPD 
include emphysema, large airway inflammation and small 
airway disease, each varying in extent and in severity in 
patients.10,11 These pathological processes are triggered by 
the complex interaction between cigarette smoke, environ-
mental toxicants, genetics and infectious agents.12,13 
Bacterial and viral insults have been shown to disrupt 
host immune defense systems in patients with COPD; 
tuberculosis is well known for causing bronchiectasis and 
COPD patients with a history of tuberculosis are well 
known to have worse outcomes.14–19
The small size of small airways renders imaging difficult 
and their inaccessibility makes obtaining biopsies challen-
ging. Hence, they have proven difficult to study and this 
explains the paucity of data about small airways disease in 
the literature. However, over the last years, there has been 
a renewed interest in small airways disease. This renewed 
interest has led to the emergence of an increased demand for 
methods to identify and quantify small airway disease accu-
rately. Currently, research efforts are being aimed at early 
detection and targeting of therapies even before symptoms 
occur and traditional spirometry results are abnormal. In this 
section of the review, we will explore the different clinical 
tests available to measure small airways disease.
Expiratory Flow
Several tests are available to assess small airways. A recent 
study conducted by Stockley et al20 showed that reduced 
Maximal Mid-Expiratory (MMEF) Flow is an early indica-
tor of lung damage in patients with alpha-one antitrypsin 
deficiency (AATD). Not only did the reduction in MMEF 
precede spirometry abnormality but it also preceded detect-
ing of emphysema using CT. As not all patients with AATD 
develop COPD, MMEF would be useful in predicting who 
are at higher risk of developing clinically significant disease.
Whilst other work has validated the use of MMEF to 
detect small airway disease,21 MMEF is not routinely used 
in clinical practice for several reasons. Firstly, it is highly 
dependent on FVC hence a false picture of airflow 
obstruction can be obtained if the patient has a smaller 
body habitus than the average for his/her height, ethnicity, 
sex and age; whilst use of lower limit of normal could 
ameliorate this error interpretation it may not eliminate it 
completely. Secondly, MMEF is derived from spirometry 
results which is effort dependent. Hence older patients, 
patients with poor physical health and those with cognitive 
impairment will struggle to carry out this test.22,23
Additionally, a study published by Bhatt et al showed that 
the use of all data points on expiratory spirometry curves to 
assess their shape is more sensitive to the detection of mild 
airway obstruction. The novel indices they used included 
Parameter D (derived from the shape of the volume–time 
curve) as well as Transition Point and Transition Distance 
(both derived from flow–volume curves). These new and 
easily obtainable metrics were found to pick up small airway 
obstruction which was previously missed using traditional 
methods.24 Similarly, the Peak Index, the number of peaks in 
the descending part of the expiratory flow–volume curve 
(adjusted for lung volume), is another novel spirometry metric 
with potential to help in detection of airflow obstruction and 
prognostication.25 Unfortunately, detailing how these novel 
indices are calculated is beyond the scope of this paper.
Impulse Oscillometry
Impulse Oscillometry (IOS) is a non-invasive pulmonary 
function test which involves superimposing soundwaves 
onto tidal breathing to measure respiratory mechanics. The 
sound waves emitted vary in frequency (usually between 5 
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and 25 Hz); higher frequencies penetrate proximal airways 
whereas lower frequencies penetrate the more distal 
airways.22 The resistance and reactance readings for different 
frequencies can be translated into the mechanical properties 
of different regions of the lungs. R20 is the resistance mea-
sured at 20Hz and represents the resistance of the large air-
ways. R5 is the resistance measured at 5Hz and represents the 
total airway resistance. The difference between these two 
values (R5-R20) represents the resistance of small airways. 
Hence, one key advantage of IOS is its ability to differentiate 
between small and large airway obstruction. IOS also pro-
vides information about elastic recoil of the small airways 
through the measurement of X5, the reactance at 5Hz. 
A decrease in elasticity is reflected by a more negative 
X5.26 Wei et al27 have shown that IOS had good correlation 
with the GOLD staging and several other studies have shown 
IOS to be more sensitive than spirometry in detecting small 
airways disease. For example, results obtained from 488 
male firefighters found that IOS identified airway abnormal-
ities even though spirometry results were within range.28 
Mondal et al29 found that IOS was more sensitive than 
spirometry in detecting bronchodilator response in children 
with sickle-cell disease. Saadeh et al30 also showed that IOS 
had greater sensitivity than spirometry for monitoring 
bronchodilator response in patients with COPD. Data from 
the Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate Endpoints (ECLIPSE) trial showed 
that smokers without COPD had an elevated AX (integrated 
area of low-frequency reactance which is a marker of small 
airway abnormality) but normal CT-scan densitometry. 
Moreover, although their FEV1 was within normal range, it 
was lower when compared to non-smoking controls.31 This 
adds to the body of evidence that IOS plays a valuable role in 
detecting small airways disease.
IOS has several advantages. It requires minimal coop-
eration from the patient and is effort independent. Hence, 
unlike MMEF, the elderly, those with poor physical 
reserve and cognitive impairment find it less challenging 
to perform IOS. It can also be used in patients post-surgery 
and acute-coronary syndromes.
Limitations of IOS include bulky and expensive equip-
ment; unlike spirometry IOS needs a laboratory. Moreover, 
there are no set reference values for different respiratory 
conditions and there is high intra-subject variability.26,32
Lung Clearance Index (LCI)
LCI is a marker of deranged ventilation and is considered 
to reflect small airway abnormalities. It is more sensitive 
than traditional spirometry in detecting small airway 
disease.33–35 LCI is obtained by measurement of the elim-
ination of an inert tracer gas such as nitrogen or helium 
through tidal breathing. Small airway disease causes 
unevenness in ventilation and this results in the inert gas 
taking longer to be washed out from the lungs and hence 
require a greater number of breaths. From these washout 
tracings, the LCI can be calculated.36
Studies have shown that LCI can be used to predict 
exacerbations in cystic fibrosis (CF) patients.37 LCI is 
currently used as an endpoint in clinical trials but there 
is currently limited data about its utility in routine clinical 
care of CF patients.38,39
LCI offers various advantages. It is effort independent 
as it involves normal tidal breathing and hence can be 
done by elderly patients. Moreover, unlike spirometry, it 
is independent of gender, age and height33,36 and hence the 
interpretation of LCI is more straightforward. It has been 
shown to have good reproducibility in patients with stable 
COPD.40
There are however several barriers that prevent LCI from 
being used as a biomarker for COPD. Fähndrich et al41 found 
that measurement of LCI in patients who were on oxygen led 
to invalid results. In addition, they found that LCI did not 
differentiate GOLD II–IV and did not correlate with 6-MWT. 
However, the high drop-out rate in this study could have 
contributed to these results. Furthermore, Horsley36 has 
argued that in patients with severe obstruction, therapeutic 
interventions targeting infection and inflammation may 
increase the heterogeneity between adequately and poorly 
ventilated parts of the lung hence worsening LCI.
Computed Tomography
Computed Tomography (CT) is the most commonly used 
imaging tool in clinical practice to assess the extent and 
distribution of emphysema. As high-resolution CT 
(HRCT) can only detect airways more than 2mm, 
microCT has been used in studies assessing the degree of 
small airway disease. One such landmark study by 
McDonough et al found that in patients with various stages 
of COPD as defined by the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) scale and in lungs 
removed from COPD patients who underwent transplanta-
tion, small airway narrowing as measured by microCT 
preceded the development of emphysema and could 
explain the increase in airway resistance present in 
COPD patients. Small airway narrowing was defined as 
the reduced number of small airways measuring between 
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2.0mm and 2.5mm in diameter detected by microCT when 
compared to controls.42 A very recent study conducted by 
Young et al11 was able to demonstrate, for the first time, 2 
trajectories in the progression of COPD: a “Tissue to 
Airway” subtype and an “Airway to Tissue” subtype. 
This study used a technique called Subtype and stage 
Inference (SuStain) to analyze CT images of GOLD 1–4 
patients and controls from the COPDGene study. SuStain 
is a novel computational technique with the ability to 
separate temporal and phenotypical heterogeneity in 
order to identify subtypes and hence patterns of disease 
progression. They found that in the “Tissue→Airway” 
subtype (n = 2354, 70.4%), small airway dysfunction and 
emphysema occurred before large airway wall abnormal-
ities whereas in the “Airway→Tissue” subtype (n = 988, 
29.6%), large airway abnormalities preceded small airway 
dysfunction and emphysema. Interestingly, they were able 
not only to verify that disease subtype remained the same 
at 5-year follow-up but they were also successful in 
demonstrating that patients in GOLD 1–2 had a steeper 
stage progression compared to GOLD 3–4 patients and 
described a steeper initial decline in FEV1 in patients 
belonging to the “Airway→ Tissue” subtype. This was 
particularly important since previous studies had reported 
opposite results when assessing disease activity in early 
disease.9,43,44 This study also identified patients with nor-
mal spirometry at risk of developing COPD. Therefore, 
CT images analyzed using SuStain could serve as 
a biomarker of early COPD and subtype hence allowing 
for targeted therapy. Moreover, it could be used in clinics 
to stratify patients, monitor progression and assess treat-
ment effect.
Biomarkers to Measure SAD
Biomarkers give indication to both normal physiological 
processes and pathological processes and are a useful 
method in observing clinical progression of disease, mon-
itoring response to therapeutic intervention and for under-
standing the underlying mechanisms of pathogenesis in 
a research setting.45 Exposure to toxicants, such as pro-
longed cigarette smoke inhalation, may influence biomar-
kers by having direct effects on the small airway 
epithelium (SAE).46
Pulmonary biomarkers can be investigated using var-
ious biofluids; sputum, bronchoalveolar lavage (BAL) and 
blood. Biomarkers detectable in induced or spontaneous 
sputum, and BAL, reflect the local environment within the 
lung where blood biomarkers represent the periphery and 
are therefore more indicative of a systemic process. 
Several studies have evaluated the source of biomarkers 
in lung disease, assessing the efficacy of each biofluid in 
giving an accurate representation of clinical parameters 
such as severity and prognosis.47,48 Such studies have 
concluded that sputum, either induced or spontaneous, 
appears to be the superior source of biomarkers in COPD 
cohorts. More research is required, however, to investigate 
longitudinal progression of sputum-derived biomarkers in 
larger cohorts as well as identifying those derived from the 
small airways. Whilst BAL also gives a clear representa-
tion of the small airways, the procedure for obtaining the 
fluid is invasive, thus impairing its utility and potentially 
its reproducibility. Despite not directly reflecting processes 
within the airways, blood biomarkers have been vastly 
studied. Although highly reproducible, blood biomarkers 
are highly confounded by other co-morbidities, particu-
larly those that are associated with systemic inflammation. 
Further, biomarkers must first be in adequate concentra-
tions within the lung for them to diffuse into the blood, 
thereby limiting detection to those biomarkers that are in 
abundance within the lung.
Ability to observe changes in the small airways is impor-
tant for understanding pathological changes at an epithelial 
level. The narrow diameter (<2mm) of the small airways 
renders them particularly susceptible to particle deposition 
and subsequent inflammation49 such that at an epithelial level 
several alterations are observed in a diseased airway com-
pared to healthy. Due to their position at the luminal inter-
face, airway epithelial cells (AECs) are exposed to inhaled 
gases and particles.50 Particularly in response to smoke 
exposure, a significant risk factor for COPD development, 
cells of the SAE undergo various morphological and func-
tional alterations (Figure 1).51 A diseased SAE undergoes 
excessive tissue repair, eventually resulting in airway 
remodeling52 with pseudostratified and ciliated epithelium 
transforming into a simple cuboidal type, and the cilia that 
remain becoming markedly shorter. Further metaplastic 
changes of ciliated cells occur, such that they differentiate 
to become squamous cells,53 and morphological and func-
tional changes are observed, notably hyper- and metaplasia 
of secretory goblet cells. The combination of depleted ciliary 
function and goblet cell hyperplasia contributes to mucous 
hypersecretion, with impaired ability for mucus to be 
removed. This, in turn, culminates in lumen obstruction.54
Increased immune cell infiltration within the alveoli, 
particularly alveolar macrophages and neutrophils, is char-
acteristic of a diseased lung. Presence of these innate 
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                            
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 354
Chukowry et al                                                                                                                                                      Dovepress
immune cells is driven by inhaled insults, namely chronic 
smoke exposure and microbial pathogens, which exacer-
bate airway remodeling through release of various proteo-
lytic enzymes and inflammatory mediators.50
Fluctuations of biomarkers in SAD may also be influ-
enced at a genetic level. Gene expression profiling of the 
SAE has revealed a distinct signature in a COPD cohort; 
increased expression of the keratin genes KRT5, −6a and 
−14 has been shown in COPD patients, compared to 
a healthy control cohort, and complements histological 
observations of squamous cell metaplasia. Further, cigar-
ette smoke exposure appears to promote the expression of 
MUC5AC, and differentiation of goblet cells, as well as 
reduced expression of SCGB1A1 in club cells.55
The following proteins have been postulated as biolo-
gical markers of SAD, based on their derivation in the 
small airways, links to epithelial processes or association 
with alveolar macrophages.
Club Cell Protein 16
Secretoglobin, family 1A, member 1 (SCGB1A1) is 
expressed almost exclusively by Club cells in the small 
airways.56 This SAE-enriched gene encodes uteroglobin, 
a secretory multifunctional protein that mediates both anti- 
inflammatory and immunomodulatory actions.57 
Uteroglobin, also referred to as Club cell protein 16 
(CC16), readily diffuses along a concentration gradient 
from the respiratory tract into the bloodstream. Although 
found in greater abundance in BAL fluid, CC16 can be 
detected in serum, urine and sputum.58 Hence, serum con-
centration of CC16 has been suggested as a biomarker of 
lung epithelium permeability and integrity.59 In fact, several 
studies have demonstrated an association with serum con-
centration of CC16 and lung function decline. In the 
ECLIPSE study cohort, serum CC16 levels were lower in 
COPD patients compared to smokers without COPD60 and 
over a 3 year period, lower CC16 levels were associated 
with lung function decline. In a separate cohort, 
a longitudinal study showed an association between low 
serum CC16 levels and accelerated lung function decline.61 
Using a cohort grouped into sustained quitters, intermittent 
quitters and continued smokers, the group demonstrated the 
lowest serum CC16 levels in the latter group.62
Whilst these studies have described a clear association 
with CC16 levels and lung function, it may be worthy to 
investigate the role of CC16 in “earlier” stage COPD, perhaps 
measuring levels in asymptomatic smokers. Given the high 
specificity of club cells to the small airways, coupled with 
their abundance, this may be a suitable biomarker of SAD.
Receptor for Advanced Glycation Endproducts 
(RAGE) and Its Ligands
Receptor for Advanced Glycation Endproducts (RAGE) is 
a well-studied biomarker of inflammatory disease, with 
increasing studies suggesting its role in small airways 
disease.63–65
With constitutive expression in type I pneumocytes, 
RAGE is expressed at uniquely high levels within the 
lungs.66–69 Common ligands of RAGE include advanced 
glycation endproducts (AGEs), S100/calgranulin proteins 
and high mobility box group 1 protein (HMGB1).70 RAGE 
recognizes the binding of these ligands to the transmem-
brane isoform (mRAGE), based on their 3D structure, to 
initiate downstream signaling, culminating in the NF-kB- 
Figure 1 Epithelial differences between normal and diseased small airways. Ciliated, cuboidal epithelial cells constitute the majority of a normal bronchiolar epithelium. In 
a diseased SAE, however, these cell types undergo metaplasia and become a more squamous phenotype. Secretory goblet cells are found in small numbers within a normal 
SAE, but under diseased conditions, increase in prevalence. By contrast, the number of secretory club cells are reduced in a diseased SAE, compared to normal, with 
a subsequent reduction in the secretion of the protective protein, CC-16. Their proposed progenitor cell, the basal cell, is however present in greater abundance in 
a diseased epithelium, compared to normal. 
Abbreviations: SAE, small airway epithelium; CC-16, club cell protein 16.
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transcription of various pro-inflammatory cytokines.71 No 
known negative feedback system has been reported 
between RAGE and its ligands and rather, it would appear 
that RAGE ligands accumulate, thereby perpetuating an 
inflammatory response.72
A soluble isoform of RAGE (sRAGE) acts as a decoy 
receptor by binding and clearing ligands of RAGE within 
extracellular fluid.72–74 Binding of ligands to sRAGE, 
rather than mRAGE, prevents the downstream inflamma-
tory cascade and for such reason, it is believed the presence 
of sRAGE serves as a protective mechanism (Figure 2).75 
Using a murine model, it was found that treatment with 
recombinant sRAGE significantly reduced neutrophil infil-
tration and NF-kB activation.76 In addition, a marked reduc-
tion of pro-inflammatory cytokine production was 
observed, with less TNF-ɑ and macrophage inflammatory 
proteins (MIP-1) present in the sRAGE treated cohort com-
pared to the vehicle.
Several studies have described involvement of RAGE 
in the presence of COPD, showing a particular association 
with emphysema.73,77 Studies have investigated the levels 
of sRAGE in both systemic biofluids, such as serum and 
plasma, as well as localized fluids such as BAL and 
sputum.63,64,75,78
Using the COPDgene cohort, Carolan et al79 discov-
ered that lower plasma concentrations of sRAGE were 
associated with increased emphysema.79 Similarly, using 
the ECLIPSE cohort, higher serum levels of sRAGE were 
associated with less emphysema.80 This trend appears to 
extend to other SAD-related pathologies; reduced levels of 
sRAGE have been detected in the BAL of both COPD 
patients and persistent asthmatics, compared to a healthy 
control cohort.64
Whilst the RAGE-signaling pathway may initially per-
form as a protective mechanism against lung insults, 
including cigarette smoke, sustained and constitutive 
expression of RAGE is likely to contribute to the patho-
genesis of chronic lung disease.
It is likely that the observed increase in RAGE signal-
ing in COPD is both by result of increased RAGE expres-
sion and decreased levels of local sRAGE within the lung. 
Assessment of RAGE and/or sRAGE may be a useful 
indicator of alveolar damage, particularly type 
I pneumocytes. Given its detectability within serum, 
RAGE may be a potential biomarker of SAD, though 
whether it is sufficiently specific to this phenotype remains 
to be determined.
Plasminogen Activator Inhibitor-1 (PAI-1)
Plasminogen activator inhibitor (PAI-1) is a serine pro-
tease inhibitor which has been associated with a number 
of inflammatory and metabolic conditions such as diabetes 
and cardiovascular disease.81–83 Several studies have 
reported an association between PAI-1 levels in the 
serum and sputum of COPD patients.84,85 Given the sug-
gested inhibition of alveolar epithelial repair by PAI-1,86 
elevated levels of the protease inhibitor may contribute to 
the pathology of SAD. As with markers centered on 
RAGE, whether PAI-1 is specific for SAD is not yet 
clear, though association with pathophysiological pro-
cesses in the airway epithelium suggests potential for this.
In a cohort of subjects with cystic fibrosis or COPD, 
PAI-1 levels were elevated in the induced sputum, when 
compared to healthy controls.87 Similarly, sputum PAI-1 
levels were increased in COPD patients, compared to 
smokers without COPD and healthy, non-smokers.88 
Authors of the latter study suggested PAI-1 levels were 
closely associated with oxidative stress-induced NF-kB 
activation in sputum macrophages. Further suggestion of 
the association of airway macrophages with PAI-1 levels 
was described by Wang et al.85 Comparison of a cohort of 
COPD patients with smokers without COPD and healthy 
non-smokers demonstrated elevated serum levels of PAI-1 
in the former. Following further division of the COPD 
cohort, based upon their smoking status, it was shown 
that PAI-1 was highest in the serum of COPD smokers. 
Moreover, serum PAI-1 levels appeared to positively 
associate with matrix metalloproteinase-9 (MMP-9) and 
its inhibitor, tissue inhibitor of matrix metalloproteinase- 
1 (TIMP-1).
Assuming both the association of PAI-1 with metabolic 
and cardiovascular diseases, and the prevalence of these 
morbidities in COPD patients, it was suspected that this 
may be the cause of PAI-1 elevation. This hypothesis was 
assessed in a cohort of moderate-to-severe COPD patients 
(GOLD stage II and III), on the premise that these groups 
display the highest prevalence of co-morbidities.89,90 As 
with previous studies, serum PAI-1 levels were elevated in 
the COPD cohort, with levels highest in GOLD stage II 
and III patients.84 Importantly, COPD was an independent 
predictor for higher PAI-1 levels following adjustment for 
age, sex, BMI and the presence of several comorbidities 
(such as diabetes, atherosclerosis and history of coronary 
artery disease). Smoking status and statin use did not 
appear to confound the level of PAI-1.
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Figure 2 Activation of transmembrane RAGE in COPD. (A) The soluble isoform of receptor for advanced glycation endproducts (sRAGE) can arise from (i) alternative mRNA splicing 
or (ii) through ADAM10-mediated proteolytic cleavage of the transmembrane isoform. (B) Under normal physiological conditions, sRAGE performs as a decoy receptor; ligands of 
RAGE preferentially bind to the soluble isoform, creating a complex that is then degraded. Studies in the context of COPD have shown an enhanced expression of transmembrane RAGE 
and its ligands, as well as a decreased concentration of sRAGE. Consequently, RAGE ligands are able to bind to their cognate receptor, initiating a downstream pathway that eventuates in 
an inflammatory response. Dia-1, a Rho effector protein, is bound to the C-terminal of RAGE and is responsible for activation of a Rho-like small GTPase: Rac1. NADPH oxidases 
(NOXes) signal through Rac1 to generate downstream reactive oxygen species (ROS). ROS are an intracellular signaling intermediate, which increase tyrosine kinase activity and initiate 
the PI3K/Akt pathway. Activation of Akt promotes the nuclear translocation of NFkB and subsequent transcription of several genes, including pro-inflammatory cytokines TNF-ɑ and 
interleukin- (IL-) 1, 2, 6, 8 and 12. Alternative pathways of NFkB initiation are achieved through p21/Ras-ERK1/2 or p38 activation. A positive feedback loop is initiated by the NFkB 
transcription of RAGE.
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Immunohistochemistry (IHC) staining of lung tissue 
revealed alveolar macrophages and epithelia as a major 
source of PAI-1 in the airways,88 consistent with studies 
that showed PAI-1 expression in alveolar macrophages and 
epithelia in murine models of pulmonary fibrosis.91,92 The 
upregulation of PAI-1 in COPD is potentially attributed to 
the prevalence of oxidative stress within the lungs of this 
population.88 Oxidant-induced nuclear translocation of 
NF-kB triggers the expression of PAI-1 and several other 
inflammatory genes, notably in alveolar macrophages.93
Matrix Metalloproteinases (MMPs)
Matrix metalloproteinases (MMPs) are a family of 
enzymes that are involved in the degradation of extracel-
lular matrix (ECM) proteins and are essential for tissue 
repair under normal physiological conditions.94 Within the 
airways, MMPs are principally produced and secreted by 
alveolar macrophages.95 Categorized based upon the type 
of ECM they degrade, a number of MMPs have been 
implicated in the pathogenesis and protease-antiprotease 
imbalance, characteristic of COPD (Figure 3). Tissue inhi-
bitor of metalloproteinases (TIMPs) are the principle inhi-
bitors of MMPs; measurement of TIMPs, alongside 
MMPs, is crucial for the understanding of the protease- 
antiprotease imbalance.96–99 Strong associations between 
MMP levels and presence of SAD, as confirmed by 
FEF25%-75% measurement (analogous to MMEF), have 
been reported.100 In spite of this, the exact role of MMPs 
in disease pathogenesis remains elusive and several con-
flicting studies suggest a complex mechanism (Table 1).
MMP-9
MMP-9, a gelatinase, has especially attracted much atten-
tion for its role in COPD. Due to its ability to degrade 
extracellular matrix proteins, promote neutrophil chemo-
taxis and mediate inflammation, MMP-9 is believed to 
contribute to the development of emphysema.101,102 
Minimal evidence exists for the role of MMP-9 in SAD, 
specifically; however given the abundance of alveolar 
macrophages within the small airways, it is likely that 
MMP-9 is a contributor to the pathogenesis of SAD as 
well as emphysema, or when airways disease is 
a precursor to emphysema.
Multiple cross-sectional studies have reported elevated 
levels of MMP-9 in COPD cohorts and inverse association 
with FEV1.96,97,103,104 Within 2 established COPD cohorts, 
SPIROMICS and COPDGene, elevated plasma MMP-9 
concentrations appeared to predict the risk of acute exacer-
bation in COPD.101 Across both cohorts, elevated MMP-9 
levels occurred more frequently in the current smokers but 
did not associate with lung function, smoking history (in 
pack years) or presence of comorbidities. In another cohort, 
levels of circulating MMP-9 appeared to sequentially 
increase with progression of GOLD stage, with the highest 
levels observed in emphysematous patients.105
Whilst protein levels of MMP-9 may be altered in 
COPD, the proteolytic activity does not appear to signifi-
cantly differ from non-COPD subjects.106,107 In fact, 
reduced MMP-9 activity was associated with increased air-
flow obstruction in a small cohort of COPD patients.106 
A possible explanation for this may be due to the observed 
increased levels of TIMP-1 in COPD subjects, which would 
inhibit the proteolytic capacity of the MMPs.108
MMP-12
The involvement of MMP-12, an elastase, has also been dis-
cussed as playing a role in the underlying disease mechanism 
of COPD. Early studies showed that MMP-12 knockout mice 
did not develop emphysema following cigarette smoke 
exposure109 and in humans, MMP-12 levels in BAL were 
shown to be up to 10-fold greater in smokers.110
Several conflicting reports have questioned the impor-
tance of MMP-12 in the context of COPD. No differences in 
the level of MMP-12 in the induced sputum between COPD 
patients and a control cohort were found.111 At 
a transcriptomic level, MMP-12 did not appear to be upre-
gulated in smokers,112 contrasting a landmark study that 
showed an association between a SNP in the MMP-12 gene 
and reduced risk of COPD development in smokers.113
In further support of the latter, MMP-12 expression was 
found to be higher in the alveolar macrophages of a current 
smoker COPD group, compared to ex-smoker COPD.114,115
In spite of conflicting evidence, it remains likely that 
MMP-12 is involved within the network of protease-driven 
mechanism of disease and rather the inconsistencies within 
the literature reflect the complexity. It may be the case that 
MMP-12 is not directly involved in the degradation of 
elastin within the lung,116 but instead contributes to alveolar 
damage through local macrophage recruitment, thus having 
a similar relationship to phenotype of COPD to MMP-9.109
MMP-8
The collagenase MMP-8 has also been associated with 
COPD, although to a lesser extent than MMP-9 and -12. In 
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a small cohort of COPD patients, MMP-8 appeared to be 
upregulated in lung tissue, with expression being enriched in 
neutrophils located in the alveoli.117 At a systemic level, both 
MMP-8 mRNA levels in PBMCs, and plasma MMP-8 
concentrations, were significantly higher in a COPD cohort, 
compared to the control group.118
To explore a possible association between smoking and 
changes in MMP expression, Ilumets et al used a cohort 
Figure 3 Prolonged smoke exposure initiates various pathways, resulting in disease of the small airways and eventuating in the onset of emphysema. Upon exposure to 
smoke, both alveolar macrophages and epithelial cells within the small airways release various chemoattractants, including interleukin (IL)-8, monocyte chemoattractant 
protein (MCP)-1, IL-1B, tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-1β. These, in turn, recruit neutrophils, monocytes and lymphocytes and 
promote their infiltration of the small airways. Alongside alveolar macrophages, neutrophils are a source of matrix metalloproteinases (MMPs) within the lungs. MMPs have 
been shown to contribute to several of the phenotypic changes in SAD, namely remodeling, inflammation, mucus hypersecretion and airflow obstruction. Recruited 
monocytes differentiate into macrophages, contributing almost to a positive feedback loop. Lymphocytes represent a major source of cytokines, particularly Th1 cytokines 
such as IFN-γ, which contribute greatly to local inflammation. Reactive oxygen species (ROS) generation by neutrophils inhibits the action of antiprotease, alpha-1 antitrypsin 
(AAT), thus causing an imbalance with its cognate protease, neutrophil elastase. Similarly, the antiprotease activity of TIMPs is hindered by ROS. By result, a large imbalance is 
observed, in favor of protease activity. Cumulatively, these prior pathways culminate in tissue remodeling and elastin degradation within the alveoli, leading to emphysema. 
Elastin fibers, as liberated by elastin degradation, activate alveolar macrophages.
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comprised of symptomatic smokers (stage 0, GOLD cri-
teria) and healthy, asymptomatic smokers. Concomitant 
analysis of MMP-8, −9, and −12 identified MMP-8 as 
the most sensitive marker of COPD.107 The induced spu-
tum of stage 0 COPD subjects contained higher MMP-8 
levels, which significantly associated with small airway 
flow parameters (MEF50 and MEF25).
In order to minimize spurious correlations being suggested, 
it is important that the activity of proteases and antiproteases is 
measured. Measurement of protease and antiprotease concen-
trations alone may be not be sufficient for confirming their role 
in COPD; detection of zymogens, inactive enzymes or those 
bound with their cognate substrate may give a false representa-
tion of underlying pathophysiology.
Table 1 Summary of Evidence Surrounding the Role of MMP-9 and -12 in COPD and Emphysema
Association Between 





MMP-9 + Beeh et al96 
(2003)
n=12 stable COPD, n=15 IPF, n=14 
healthy controls
Induced sputum concentration of MMP-9 
higher In COPD vs IPF and controls (p<0.05)
+ Brajer et al103 
(2008)
n=23 COPD, n=23 healthy controls Increased MMP-9 levels in serum of COPD, 
compared to control (p=0.0005)
+- Wells et al101 
(2018)
n=1053 SPIROMICS, n=140 
COPDGene
Elevated MMP-9 in plasma of 9% SPIROMICS 
and 29% COPDGene. Independently 
associated with risk of AECOPD.
+- Higashimoto 
et al97 (2005)
n=72 COPD, n=66 control, n=26 
asthma
No difference in serum MMP-9 concentration 
between groups. Serum MMP-9/TIMP-1 molar 
ratio significantly lower in COPD cohort, 
compared to control (p<0.0001).
MMP-12 + Demedts 
et al110 (2006)
n=28 stable COPD, n=14 healthy 
smokers, n=20 never smokers, n=14 
former smokers
MMP-12 levels in BAL between 4–10 fold 
greater in smokers (p=0.0002)
+ Hunninghake 
et al113 (2009)
n=127 eoCOPD, n=378 NETT, 
n=1487 Lovelace, n=1468 NAS
SNP in the MMP-12 gene associated with 




n=39 COPD patients (of which n=22 
smokers, n=17 ex-smokers), n=8 
“healthy” smokers, n=11 healthy non- 
smokers
% of MMP-12+ alveolar macrophages did not 
differentiate smoking status in COPD cohort. 
Increased MMP-12 concentration in induced 
sputum of COPD, compared to healthy cohorts 




n=54 patients undergoing surgical 
resection for lung carcinoma (see if 
can differentiate the cohort)
MMP-12 mRNA expression higher in cultured 
alveolar macrophages isolated from current 
smokers, compared with former smokers. 
Negative correlation between MMP-12 
expression and DLCO.
- Imai et al112 
(2001)
n=23 patients with emphysema, n=3 
ɑ1ATD-associated emphysema, n=8 
normal controls, n=3 normal smokers
No upregulation of MMP-12 in type II 
pneumocytes isolated from emphysema 
patients, compared to control
Notes: (+): studies that have displayed an association or significant difference of MMPs in a diseased cohort; (+-): studies that have found both associations/differences as 
well as negative data; (-): studies that have shown no association/differences between MMPs in their diseased vs control cohorts. COPD: chronic obstructive pulmonary 
disease; IPF: idiopathic pulmonary fibrosis; SPIROMICS: SubPopulations and InteRmediate Outcome Measures In COPD Study – a cohort of COPD patients; COPDGene: 
a cohort of COPD patients; eoCOPD: Boston early-onset COPD – a cohort of COPD patients <53 years of age; NETT: National Emphysema Treatment Trial – a cohort of 
severe COPD patients with evidence of emphysema onset; Lovelace: a cohort of smokers; NAS: Normative Aging Study – a cohort of healthy controls with median age of 
41.5 years; ɑ1ATD: alpha-1 antitrypsin deficiency.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                            
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 360
Chukowry et al                                                                                                                                                      Dovepress
Conflicting literature surrounding the involvement of 
MMPs in chronic lung disease may imply a complex net-
work constitutes the underlying pathophysiology, though 
some studies could have been affected by small sample 
sizes.
Consolidation of data reporting alterations in MMP 
protein levels, and their localization within alveolar 
space, highlights them as a potential biomarker of small 
airway dysfunction. On the assumption that alveolar 
macrophages are a major source of MMPs within the air-
ways, detection and measurement of these enzymes may 
be indicative of damage within the small airways.
Discussion
Small airway dysfunction contributes immensely to the 
pathogenesis of COPD.5,7 Current clinical detection of 
SAD involves the measurement of various physiological 
parameters, such as gas transfer, or the use of (high resolu-
tion) CT imaging.119
Such assessments are not always specific to small air-
way abnormalities and often require the use of specialized 
equipment, which limits their capacity in research. Hence, 
biological markers are required to improve the understand-
ing of underlying mechanisms, which may in turn guide 
clinical management. Careful consideration must be taken 
in assessing and potentiating biomarkers. Firstly, the bio-
marker must display specificity to the small airways, with 
strong evidence supporting its role in the pathophysiology 
of disease. Secondly, and important in a clinical context, is 
the ability of the biomarker to be readily detectable in 
biofluids. Blood and induced sputum are non-invasive 
fluids that give representation of the systemic and local 
environments, respectively. Reproducibility is especially 
important for the monitoring of disease progression in 
individuals with COPD and may influence clinical 
management.
Whilst our review has delineated some plausible bio-
markers of SAD it was also apparent from the results that 
a significant area of unmet need is the differentiation 
between SAD and emphysema in COPD patients. 
Currently, only limited studies have shown an association 
between biomarker levels and other physiological mea-
sures of small airway function. It remains unclear whether 
the biological markers are associated with SAD alone, or 
both SAD and emphysema. Further research must be con-
ducted that investigates the presence of biological markers 
with already-established physiological measures of SAD, 
with consideration for possible overlap between the two 
disease phenotypes.
In order to better target therapy, it is crucial to differ-
entiate age-related decline in function of tissues to disease. 
Physiological “normal” aging of the lung involves loss of 
elastic recoil,120 increased air trapping,121 
hyperinflation,122 decline in FEV1.123 Due to the simila-
rities between emphysema and age-related gas trapping, 
particularly on CT, controversies exist over whether 
emphysema is a feature of aging in healthy elderly 
people.124,125 Small airway abnormalities also occur as 
a normal part of the aging process. However, when these 
small airway abnormalities develop earlier and to a greater 
extent, a disease develops – small airway disease. COPD 
has been described as “accelerated aging of the 
lung”.126,127 Specialized CT analysis software with the 
ability to better visualize small airways, whilst also quan-
tifying emphysema may be one way to aid differentiation 
of aging and disease.
Parametric Response Mapping is one such recent CT 
analysis software with the ability to differentiate emphy-
sema from gas trapping associated with functional small 
airway abnormality (PRMFSA). Martinez et al used PRM 
to analyze inspiratory/expiratory CT imaging of patients 
without airflow obstruction or mild to moderate airflow 
obstruction involved in SPIROMICS (Subpopulations and 
Intermediate Outcome Measures in COPD Study) and 
made several important observations. Firstly, they found 
a strong link between PRMFSA and increased FVC. 
Secondly, in patients with the same degree of airway 
obstruction, those who were older were subjected to 
a greater extent of PRMFSA. Moreover, in those without 
airflow obstruction PRMFSA increased with age, irrespec-
tive of respiratory symptoms and smoking status. These 
findings help to shed more light on normal aging of the 
lungs and what can be classified as disease. Small airway 
abnormality associated with normal aging have minimal 
effect of FEV1 decline but contribute to increase FVC (by 
gas trapping). Hence healthy, elderly patients are at risk of 
being wrongly diagnosed with COPD due to their FEV1/ 
FVC ratio being less than <0.7.128 Furthermore, they 
found a low burden of emphysema in elderly patients 
without airflow obstruction.129 This study provides evi-
dence that the development of emphysema does not form 
part of the normal physiological process of aging.
The identification of the key role played by small air-
ways in the pathogenesis of asthma and COPD has 
resulted in a need for more effective drug delivery 
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mechanisms to the small airways. The ability of extrafine 
drug particles to be better distributed in the small airways 
has been associated with better asthma control.130,131 
However, a study investigating the effectiveness of beclo-
methasone dipropionate/formoterol fumarate (BDP/FF) 
extrafine combination versus fluticasone propionate/salme-
terol (FP/S) combination in COPD patients 
(NCT01245569) found that both drugs improved shortness 
of breath to the same extent although BDP/FF had faster 
onset of bronchodilation.132 As this study used changes in 
FEV1 as outcome measure, it can be argued that FEV1 is 
not a sensitive measure of the functional status of the small 
airways and results might have been different if pulmonary 
function tests more sensitive at measuring the function of 
small airways were used.
Conclusion
It is crucial not only to detect small airways disease early 
so that treatment can be targeted to slow down the trajec-
tory of disease but also to be able to separate normal aging 
from a pathological process. Whilst specialized radiologi-
cal and physiological tests in early disease show promise, 
addition of biomarkers of pathological processes is in its 
infancy such that further research in highly phenotyped 
patients is warranted.
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